Dr. Wang and Prof. Wang from Xiamen University Affiliated Cardiovascular Hospital have successfully guided the completion of Eastern Indonesia's first transcatheter aortic valve implantation (TAVI). The procedure utilized the innovative VitaFlow Liberty® medical device developed by MicroPort, achieving a significant milestone in TAVI commercialization in Indonesia.

Indonesia's First TAVI Procedure

At Dr. Soetomo General Academic Hospital in Indonesia, Dr. Wang's team collaborated with local experts to successfully complete a challenging TAVI procedure. This surgery presented a major challenge due to the patient's Type0 bicuspid aortic valve with severe stenosis and regurgitation, compounded by significant calcification and complex anatomical issues. The surgical team needed to precisely analyze the patient's cardiac structure and select the appropriate instruments and strategies to ensure the success of the procedure.

Surgical Process:Following a detailed preoperative assessment and thorough preparation, the team used an 18mm balloon for pre-dilation, and then successfully implanted the VitaFlow Liberty® 24mm valve. During the surgery, the valve was accurately positioned and the implantation outcome was satisfactory. Postoperatively, the patient's hemodynamics showed significant improvement, with only minimal paravalvular leakage and no conduction disturbances, leading to a smooth recovery.

VitaFlow Liberty®: An Innovative Breakthrough in TAVI Devices

VitaFlow Liberty® is the only electric reusable TAVI system globally, developed by MicroPort. It builds on the design advantages of the VitaFlow® series and features groundbreaking upgrades in valve design and delivery system. The device employs a hybrid self-expanding stent, bovine pericardial leaflets, and a high-density PET skirt design, offering high radial support, enhanced coaxial release, and reduced incidence of paravalvular leakage. Additionally, the innovative dual-strut helical structure improves the delivery system's stability and flexibility.

With over 47 million patients worldwide suffering from aortic stenosis and regurgitation, TAVI has become the preferred treatment due to its minimally invasive nature, rapid recovery, and improvement in quality of life. MicroPort's VitaFlow series has been adopted in nearly 100 key hospitals worldwide. The recent CE approval of VitaFlow Liberty® accelerates MicroPort's global expansion, bringing new technological innovations and development opportunities to the global cardiac valve intervention field.